中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (8): 759-766.doi: 10.35541/cjd.20260031

• 论著 • 上一篇    下一篇

电子线照射治疗卡波西肉瘤的疗效及安全性相关因素研究

赵舒文    张景展    康晓静    

  1. 新疆维吾尔自治区人民医院皮肤性病科  新疆皮肤性病临床医学研究中心  新疆皮肤病研究重点实验室,乌鲁木齐  830001
  • 收稿日期:2026-01-14 修回日期:2026-05-03 发布日期:2026-08-03
  • 通讯作者: 康晓静 E-mail:drkangxj666@163.com
  • 基金资助:
    新疆维吾尔自治区重点研发专项(2024B03039-1,2024B03039-2)

Efficacy and safety of electron beam radiation therapy for Kaposi sarcoma and factors associated with treatment outcomes

Zhao Shuwen, Zhang Jingzhan, Kang Xiaojing   

  1. Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region,Xinjiang Clinical Research Center for Dermatology and Venereology,Xinjiang Key Laboratory of Dermatology Research, Urumqi 830001, China
  • Received:2026-01-14 Revised:2026-05-03 Published:2026-08-03
  • Contact: Kang Xiaojing E-mail:drkangxj666@163.com
  • Supported by:
    Key Research and Development Program of Xinjiang Uygur Autonomous Region(2024B03039-1,2024B03039-2)

摘要: 【摘要】 目的 评估电子线照射治疗卡波西肉瘤的临床疗效与安全性,分析影响疗效的相关因素。方法 本研究为单中心回顾性队列研究。回顾2006年1月至 2025年2月期间就诊于新疆维吾尔自治区人民医院并接受电子线照射治疗的卡波西肉瘤患者资料。所有患者均接受6 ~ 12 MeV电子线病灶区域垂直照射,个体化制定总剂量与分割方案;疗效评价参照实体肿瘤临床疗效评价标准分为完全缓解、部分缓解、疾病稳定和疾病进展;不良反应按放射治疗肿瘤协作组(RTOG)放射性损伤标准分级。采用多因素Logistic回归分析疗效影响因素,并计算比值比(OR),采用Cox比例风险模型分析总生存期相关因素,并计算风险比(HR)。结果 纳入48例卡波西肉瘤患者,男44例(91.7%),女4例(8.3%),病程21(7.3,60.0)个月。纳入137处病灶进行分析,病灶接受的总放射剂量为34(24,44)Gy,照射次数17(12,22)次;治疗深度以0.5 cm(61处,44.5%)和1.0 cm(50处,36.5%)为主;88处病灶达到客观缓解(64.2%),126处达到疾病控制(92.0%)。根据放射总剂量分组,低剂量组(< 30 Gy)病灶53处,中剂量组(30 ~ < 40 Gy)20处,高剂量组(≥ 40 Gy)64处;低剂量组的客观缓解率(26处,49.06%)显著低于中剂量组(15处,75.00%)和高剂量组(47处,73.44%),均P < 0.05。多因素分析显示,较高的放射总剂量、更深的治疗深度以及临床分期处于结节期是病灶获得客观缓解的独立有利因素(均P < 0.05)。随访时间3 ~ 108个月,共有69处病灶(50.4%)复发,低剂量组的复发率(35处,66.04%)高于高剂量组(25处,39.06%,P = 0.009),较高的总剂量亦是降低复发风险的独立保护因素(HR = 0.96,95% CI:0.94 ~ 0.98,P < 0.001)。多因素Cox分析显示,复发是影响无进展生存期的最主要因素,场外复发的疾病进展或死亡风险最高(HR = 21.14,95% CI:5.58 ~ 80.04,P < 0.001)。安全性方面,共有41处(29.93%)出现治疗相关不良反应,39处发生急性放射损伤,33处发生晚期慢性不良反应;无4级及以上晚期慢性不良反应,亦无治疗相关死亡事件。结论 电子线放射后卡波西肉瘤安全、有效,总剂量 ≥ 30 Gy可显著提升肿瘤缓解率并降低复发风险,改善患者预后。

关键词: 肉瘤, 卡波西, 电子线照射, 疗效, 安全性, 影响因素分析, 生存分析

Abstract: 【Abstract】 Objective To evaluate the clinical efficacy and safety of electron beam radiation therapy for Kaposi sarcoma, and to analyze factors associated with treatment outcomes. Methods This was a single-center retrospective cohort study. Clinical data were retrospectively collected from patients with Kaposi sarcoma who received electron beam radiation therapy at the People′s Hospital of Xinjiang Uygur Autonomous Region between January 2006 and February 2025. All patients received perpendicular irradiation of the lesion area using 6 - 12 MeV electron beams, with individualized total radiation doses and fractionation schedules. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors, and categorized as complete response, partial response, stable disease, or progressive disease. Adverse reactions were graded according to the Radiation Therapy Oncology Group radiation morbidity scoring criteria. Multivariable logistic regression analysis was performed to identify factors influencing treatment response, and odds ratios (ORs) were calculated. Cox proportional hazards regression analysis was used to identify factors associated with overall survival, and hazard ratios (HRs) were calculated. Results A total of 48 patients with Kaposi sarcoma were included, comprising 44 males (91.7%) and 4 females (8.3%), with the disease duration being 21 (7.3, 60.0) months. A total of 137 lesions were analyzed. The total radiation dose was 34 (24, 44) Gy, and the number of fractions was 17 (12, 22). The treatment depths were mainly 0.5 cm (61 lesions, 44.5%) and 1.0 cm (50 lesions, 36.5%). Objective response was observed in 88 lesions (64.2%), and the condition was controlled in 126 lesions (92.0%). According to the total radiation dose, lesions were categorized into the low-dose group (< 30 Gy, 53 lesions), intermediate-dose group (30 to < 40 Gy, 20 lesions), and high-dose group (≥ 40 Gy, 64 lesions). The objective response rate was significantly lower in the low-dose group (26 lesions, 49.06%) than in the intermediate-dose group (15 lesions, 75.00%) and high-dose group (47 lesions, 73.44%) (both P < 0.05). Multivariable analysis showed that higher total radiation dose, greater treatment depth, and nodular-stage lesions were independent favorable factors associated with objective response (all P < 0.05). During a follow-up period of 3 - 108 months, 69 lesions (50.4%) recurred. The recurrence rate was significantly higher in the low-dose group (35 lesions, 66.04%) than in the high-dose group (25 lesions, 39.06%; P = 0.009). A higher total radiation dose was an independent protective factor against recurrence (HR = 0.96, 95% CI: 0.94 - 0.98, P < 0.001). Multivariable Cox regression analysis showed that recurrence was the most important factor associated with progression-free survival, with out-of-field recurrence conferring the highest risk of disease progression or death(HR = 21.14, 95% CI: 5.58 - 80.04, P < 0.001). Regarding safety, treatment-related adverse reactions occurred in 41 lesions (29.93%), with acute radiation injury observed in 39 lesions and late-onset chronic adverse reactions in 33. No grade 4 or 5 late-onset chronic adverse reactions or treatment-related deaths were observed. Conclusions Electron beam radiation therapy is a safe and effective treatment for Kaposi sarcoma. A total radiation dose of ≥ 30 Gy could significantly improve tumor response rates, reduce the risk of recurrence, and improve patient outcomes.

Key words: Sarcoma, Kaposi, Electron beam radiation, Efficacy, Safety, Root cause analysis, Survival analysis

引用本文

赵舒文 张景展 康晓静. 电子线照射治疗卡波西肉瘤的疗效及安全性相关因素研究[J]. 中华皮肤科杂志, 2026,59(8):759-766. doi:10.35541/cjd.20260031

Zhao Shuwen, Zhang Jingzhan, Kang Xiaojing. Efficacy and safety of electron beam radiation therapy for Kaposi sarcoma and factors associated with treatment outcomes[J]. Chinese Journal of Dermatology, 2026, 59(8): 759-766.doi:10.35541/cjd.20260031